On Friday, Geron Corp (GERN) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.14 or 3.16% from the prior close of $4.43. The stock opened at $4.47 and ...

On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.6 which represents a slight increase of $0.06 or 3.90% from the prior close of $1.54. The stock opened at ...

Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...

In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Current Position of Regeneron Pharmaceuticals Currently trading with a volume of 389,940, the REGN's price is down by -1.07%, now at $1034.78. RSI readings suggest the stock is currently may be ...

Medicines the company is developing for eczema and myasthenia gravis met their objectives in Phase 3 trials. But analysts weren’t convinced they can compete with available alternatives.

Capstan Therapeutics to participate in Goldman Sachs Cell Therapy Day 2024 and Leerink Partners Biopharma Private Company Connect.